<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000068.pub2" GROUP_ID="MENSTR" ID="800599072816032748" MERGED_FROM="" MODIFIED="2010-09-21 02:03:31 +0200" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Short title (no longer in use): Endometriosis:danazol:pain&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 13:01:02 +1300" NOTES_MODIFIED_BY="jane clarke" REVIEW_NO="081" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.8">
<COVER_SHEET MODIFIED="2010-09-21 02:03:31 +0200" MODIFIED_BY="Jane Clarke">
<TITLE>Danazol for pelvic pain associated with endometriosis</TITLE>
<CONTACT MODIFIED="2010-09-21 02:03:31 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="9CE26E7F82E26AA200CD32E53036321F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Cindy</FIRST_NAME><LAST_NAME>Farquhar</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>c.farquhar@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>FMHS Park Road</ADDRESS_1><ADDRESS_2>Grafton</ADDRESS_2><CITY>Auckland</CITY><ZIP>1003</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 6309943</PHONE_1><FAX_1>+64 9 6309858</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-09-21 02:03:31 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="9CE26E7F82E26AA200CD32E53036321F" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Cindy</FIRST_NAME><LAST_NAME>Farquhar</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>c.farquhar@auckland.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>FMHS Park Road</ADDRESS_1><ADDRESS_2>Grafton</ADDRESS_2><CITY>Auckland</CITY><ZIP>1003</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 6309943</PHONE_1><FAX_1>+64 9 6309858</FAX_1></ADDRESS></PERSON><PERSON ID="8013" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><LAST_NAME>Prentice</LAST_NAME><POSITION>University Lecturer</POSITION><EMAIL_1>ap128@cam.ac.uk</EMAIL_1><EMAIL_2>ap128@mole.bio.cam.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>Rosie Maternity Hospital</ORGANISATION><ADDRESS_1>Robinson Way</ADDRESS_1><CITY>Cambridge</CITY><ZIP>CB2 2SW</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1223 336876</PHONE_1><PHONE_2>+44 1223 336881</PHONE_2><FAX_1>+44 1223 215327</FAX_1></ADDRESS></PERSON><PERSON ID="4987" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Amita</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Singla</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>amita.singla@nwahs.sa.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>The Queen Elizabeth Hospital</ORGANISATION><ADDRESS_1>28 Woodville Road</ADDRESS_1><ADDRESS_2>Woodville</ADDRESS_2><CITY>Adelaide</CITY><ZIP>5011</ZIP><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 8 8222 6892</PHONE_1><FAX_1>+61 8 8222 6050</FAX_1></ADDRESS></PERSON><PERSON ID="4968" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Vanessa</FIRST_NAME><LAST_NAME>Selak</LAST_NAME><POSITION>Public Health Physician</POSITION><ADDRESS><DEPARTMENT>Waitemata District Health Board</DEPARTMENT><ORGANISATION>Level 1, 15 Shea Terrace</ORGANISATION><ADDRESS_1>Private Bag 93-503</ADDRESS_1><ADDRESS_2>Takapuna</ADDRESS_2><CITY>Auckland</CITY><ZIP>1003</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+649486 8920 ext.2622</PHONE_1><FAX_1>+649441 8957</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-07 21:10:45 +1300" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Minor update: 8/30/99&lt;/p&gt;&lt;p&gt;New studies sought but none found: 6/11/03&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 6/15/07&lt;/p&gt;&lt;p&gt;Conclusions changed: 8/30/01&lt;/p&gt;" NOTES_MODIFIED="2008-11-07 21:10:45 +1300" NOTES_MODIFIED_BY="Jane Clarke">
<UP_TO_DATE>
<DATE DAY="15" MONTH="6" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="6" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2010-09-21 01:18:54 +0200" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;A search for randomised controlled trials in July 2001 did not identify any further trials. The outcomes were revised and only outcomes that were considered clinically relevant were included. &lt;br&gt;A search for randomised controlled trials in June 2003 did not identify any further trials.&lt;br&gt;A search for randomised controlled trials in November 2004 did not identify any new trials. The search strategy for the review was updated to include new terms and the text of the review was edited.&lt;br&gt;A further search in 2007 identified one new randomised controlled trial which was included.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 12:54:10 +1300" NOTES_MODIFIED_BY="jane clarke"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 01:18:54 +0200" MODIFIED_BY="Jane Clarke"><DATE DAY="20" MONTH="9" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2008-11-11 12:54:10 +1300" MODIFIED_BY="jane clarke">
<DATE DAY="10" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>The findings of this review are regarded as being stable</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2010-09-21 01:18:54 +0200" MODIFIED_BY="Jane Clarke"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 01:18:54 +0200" MODIFIED_BY="Jane Clarke">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="6" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Obstetrics and Gynaecology, University of Auckland</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Wellington Medical Research Foundation</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department of Obstetrics and Gynaecology, University of Cambridge</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Wellington School of Medicine</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-11 12:58:35 +1300" MODIFIED_BY="jane clarke">
<SUMMARY>
<TITLE>Danazol for pelvic pain associated with endometriosis</TITLE>
<SUMMARY_BODY>
<P>Danazol reduces the painful symptoms of endometriosis but has androgenic effects. Endometriosis is a painful condition where endometrial tissue grows outside the uterus. It can cause cysts and infertility. Danazol is a hormone that produces male characteristics as well as weight gain and acne. It does, however, relieve the painful symptoms of endometriosis, although the side effects can be unacceptable. The improvement was still present six months after treatment was stopped. There was some evidence that women who took danazol were satisfied with the treatment compared with women who had inactive treatment. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Endometriosis is defined as the presence of endometrial tissue (stromal and glandular) outside the normal uterine cavity. Conventional medical and surgical treatments for endometriosis aim to remove or decrease the deposits of ectopic endometrium. The observation that hyper androgenic states (an excess of male hormone) induce atrophy of the endometrium has led to the use of androgens in the treatment of endometriosis. Danazol is one of these treatments. The efficacy of danazol is based on its ability to produce a high androgen and low oestrogen environment (a pseudo menopause) which results in atrophy of the endometriotic implants and thus an improvement in painful symptoms. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effectiveness of danazol compared to placebo or no treatment in the treatment of the symptoms and signs, other than infertility, of endometriosis in women of reproductive age.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Menstrual Disorders and Subfertility Group Specialised Register of trials (searched April 2007), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2007), and MEDLINE (1966 to April 2007). In addition, all reference lists of included trials were searched, and relevant drug companies were contacted for details of unpublished trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials in which danazol (alone or as adjunctive therapy) was compared to placebo or no therapy. Trials which only reported infertility outcomes were excluded. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Only five trials met the inclusion criteria and two authors independently extracted data from these trials. All trials compared danazol to placebo. Three trials used danazol as sole therapy and three trials used danazol as an adjunct to surgery. Although the main outcome was pain improvement other data relating to laparoscopic scores and hormonal parameters were also collected.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Treatment with danazol (including adjunctive to surgical therapy) was effective in relieving painful symptoms related to endometriosis when compared to placebo. Laparoscopic scores were improved with danazol treatment (including as adjunctive therapy) when compared with either placebo or no treatment. Side effects were more commonly reported in those patients receiving danazol than for placebo.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Danazol is effective in treating the symptoms and signs of endometriosis. However, its use is limited by the occurrence of androgenic side effects.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-11 12:58:35 +1300" MODIFIED_BY="jane clarke">
<BACKGROUND>
<P>Endometriosis is a common gynaecological condition affecting women in their reproductive years. Endometriosis is defined as the presence of endometrial tissue (stromal and glandular) outside the normal uterine cavity. The condition presents most commonly with symptoms of pelvic pain or infertility, or both, or the presence of an endometriotic cyst (<LINK REF="REF-Barbieri-1990" TYPE="REFERENCE">Barbieri 1990</LINK>). </P>
<P>The development of endometriosis remains unclear. It is probable that endometriosis arises by the dissemination of endometrium to other sites, either by retrograde menstruation or by lymphatic and haemato genous routes, where they are subsequently established as deposits of ectopic endometrium (<LINK REF="REF-McLaren-1996" TYPE="REFERENCE">McLaren 1996</LINK>). It is assumed that the presence of these ectopic deposits gives rise to the symptoms associated with the condition (<LINK REF="REF-Rock-1992" TYPE="REFERENCE">Rock 1992</LINK>). </P>
<P>Conventional medical and surgical treatments for endometriosis aim to remove or decrease deposits of ectopic endometrium. They achieve this either by inducing atrophy within the hormonally dependent ectopic endometrium or by destroying the endometriotic implant. Surgery is also used to alleviate painful symptoms by dividing adhesions and interrupting neural pathways. </P>
<P>The observation that hyper androgenic states (an excess of male hormone) induce atrophy of the endometrium has led to the use of androgens in the treatment of endometriosis (<LINK REF="REF-Barbieri-1990" TYPE="REFERENCE">Barbieri 1990</LINK>). Androgens are steroid hormones that promote male characteristics. One such androgen is danazol, a synthetic isoxazole derivative chemically related to 17-ethinyl testosterone. Danazol has a complex mechanism of action. The effects of danazol are due to its inherent androgenic properties and its ability to increase the concentration of free testosterone by binding to sex hormone-binding globulin (the concentration of which is decreased by danazol) to displace testosterone. Furthermore, danazol inhibits steroid production in the ovary, resulting in a decrease in ovarian oestrogen production (Barbieri 1977). In addition, danazol interferes with follicle stimulating hormone (FSH) and luteinizing hormone (LH) secretion by the pituitary. Danazol also has a specific inhibitory effect upon endometrial growth. Thus, the efficacy of danazol is based on its ability to produce a high androgen and low oestrogen environment (a pseudo menopause) which results in the atrophy of endometriotic implants and thus an improvement in painful symptoms (<LINK REF="REF-Barbieri-1990" TYPE="REFERENCE">Barbieri 1990</LINK>). </P>
<P>The cost of endometriosis is high in both economic and human terms. Treatment that is available is dependent not only upon available resources but also upon the preference and skills of the individual gynaecologist. This review aims to evaluate the role of danazol in the treatment of endometriosis. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the effectiveness of danazol compared to placebo or no treatment the treatment of painful symptoms associated with endometriosis in women of reproductive age.<BR/>The effect of danazol on fertility in women with endometriosis is dealt with in another review (<LINK REF="REF-Hughes-2007" TYPE="REFERENCE">Hughes 2007</LINK>).</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-11 12:53:29 +1300" MODIFIED_BY="jane clarke">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised controlled trials (RCT's) of the use of danazol in the treatment of endometriosis in women of reproductive age.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>This review considered studies that included women of reproductive age with the diagnosis of endometriosis made by direct visualisation (laparoscopy or laparotomy). This included patients who were asymptomatic and where endometriosis was an incidental finding. In such patients, symptoms were obviously not one of the studied outcomes but American Fertility Society (AFS) scores and side effects were studied. Studies of women who had undergone surgery and were given postoperative medical therapy were also included (see also the review on postoperative medical therapy by <LINK REF="REF-Yap-2004" TYPE="REFERENCE">Yap 2004</LINK>). Quasi-randomised trials were not included in this review. </P>
<P>Studies in any appropriate care setting (secondary or tertiary) were considered. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Studies were included that compared danazol, as sole or adjunctive therapy, with placebo or no treatment. Any dosage or duration of treatment was included. Studies in which surgery may have been performed at the time of initial diagnosis were analysed separately. </P>
<P>The review did not consider comparison of danazol with the following: <BR/>
</P>
<UL>
<LI>gonadotrophin releasing hormone (GnRH) agonists; </LI>
<LI>progestogen; </LI>
<LI>progestogens and oestrogen; </LI>
<LI>the surgical treatments of ablation or excision of endometriotic deposits; </LI>
<LI>surgical treatments involving removal of pelvic organs (e.g. hysterectomy); </LI>
<LI>treatments that attempt to interrupt neural pathways (e.g. LUNA or presacral neurectomy); </LI>
<LI>alternative or complementary therapies. </LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Both subjective and objective outcome measures were considered. Outcome measures were considered both during and at the end of treatment as well as after a drug-free period. <BR/>Subjective relief of any or all of the symptoms or signs listed below were considered using both quantitative measures such as visual analogue scales; or qualitative measures such as symptom free, better, the same or worse. </P>
<P>Objective evaluation of improvement of endometriotic implants was assessed by the American Fertility Society (AFS) classification of endometriosis (AFS 1979). A distinction was made between those studies where repeat laparoscopy occurred during treatment and studies that repeated the laparoscopy after treatment. </P>
<P>Other outcome measures that were considered included side effects (listed below) both in the short term during therapy and long term extending beyond the treatment period. </P>
<P>Compliance with therapy and withdrawal from studies due to side effects were also considered, as was recurrence of the disease (symptoms, signs and laparoscopic evidence of disease). </P>
<P>The symptoms and signs considered were as follows. <BR/>
<B>(1) Symptoms <BR/>
</B>
<B>
<I>(a) Major - pain </I>
</B>
<BR/>(i) general or a total pain score<BR/>(ii) dysmenorrhoea <BR/>(iii) pelvic <BR/>(iv) dyspareunia <BR/>(v) defecation or dysuria <BR/>(vi) low back <BR/>
<B>
<BR/>
</B>
<B>
<I>(b) Minor </I>
</B>
<BR/>Any other symptom ascribed to endometriosis and studied in any relevant trial were to be considered <BR/>
<B>
<BR/>(2) Signs <BR/>
</B>
<B>
<I>(a) Major </I>
</B>
<BR/>(i) pelvic tenderness <BR/>(ii) induration </P>
<P>
<B>
<I>(b) Minor </I>
</B>
<BR/>(i) beading nodularity and tenderness of uterosacral ligaments on vaginal examination <BR/>(ii) palpable adnexal masses <BR/>(iii) uterus - position and fixity </P>
<P>
<B>(3) Adverse effects </B>
<B>
<I>
<BR/>(a) Major </I>
</B>
<BR/>(i) hypo estrogenic (low oestrogen levels) including decreased breast size, atrophic vaginitis, hot flushes, emotional lability, vaginal dryness, changes in libido <BR/>(ii) androgenic (excess male hormone) including weight gain, oedema, muscle cramps, acne, oily skin, sweating, deepening of voice, hirsutism </P>
<P>(b) Other <BR/>(i) nausea <BR/>(ii) headaches <BR/>(iii) dizziness <BR/>(iv) fatigue <BR/>(v) depression <BR/>(vi) nervousness <BR/>(vii) insomnia <BR/>(viii) skin rash <BR/>(ix) abnormal bleeding pattern </P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-11 12:53:29 +1300" MODIFIED_BY="jane clarke">
<P>(1) We searched the Menstrual Disorders and Subfertility Group Specialised Register for any trials (searched April 2007). See Review Group for more details on the make up of this Specialised Register.</P>
<P>(2) The Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library 2007, Issue 3 was searched in all fields.</P>
<P>(3) The following databases were searched see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>(4) The citation lists of relevant publications, review articles, and included studies were also searched.</P>
<P>(5) All UK distributors of danazol were approached for details of unpublished trials of danazol as known to or undertaken by them or their parent companies.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>The assessment of the quality of trials identified by the search strategy was undertaken by two of the review authors who were unblinded to the source of the studies. Where uncertainty existed regarding suitability for inclusion, or where discrepancy existed between the two review authors, a third review author made a further assessment. Authors were contacted to determine pre-publishing data manipulation (such as exclusion of patients from the final analysis), method of allocation concealment and to provide additional data, if required. The quality of trials for inclusion was assessed using a standard checklist developed by the Review Group. The quality of allocation concealment was graded as either A (adequate), B (unclear) or C (inadequate). For all trials included, the following information was collected: the method of randomisation, allocation concealment, blinding, the possibility of performing an intention-to-treat analysis, the intended interventions and the outcomes measured. </P>
<P>Data was extracted by two assessors who were unblinded. One of the assessors was an expert in the content matter. For data extraction, forms developed according to Cochrane guidelines were utilised. Attempts were made to contact the appropriate author(s) to obtain data if these were presented in a graphical form only in the trial reports. If these attempts failed, data were extracted directly from the graphs by two assessors. </P>
<P>Statistical analysis was performed in accordance with the guidelines for statistical analysis developed by the Cochrane Collaboration and in the Cochrane Handbook for Systematic Reviews of Interventions. Heterogeneity between the results of different studies was examined by inspecting the scatter in the data points, the overlap in their confidence intervals and, more formally, by checking the results of the chi-squared tests and the I-squared value. A priori, it was planned to look at the postoperative studies separately. </P>
<P>Where possible, the outcomes were pooled statistically. For dichotomous data (for example, proportion of patients with a specific adverse side effect) results for each study were expressed as a relative risk (RR) with 95% confidence intervals (CI) and combined for meta-analysis with RevMan software using the Peto-modified Mantel-Haenszel method. </P>
<P>Continuous differences between groups in the meta-analysis (for example, multidimensional pain scores) were shown as weighted mean difference (WMD) and 95% confidence interval (CI). A fixed-effect approach was used unless there was significant heterogeneity as determined by Chi-squared test or the I-squared value, in which case results were investigated using a random-effects statistical model. Sources of heterogeneity were investigated as stated above. </P>
<P>It is unlikely that further RCTs of danazol will be undertaken and further updates are not planned unless new studies are reported. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-11 12:58:35 +1300" MODIFIED_BY="jane clarke">
<STUDY_DESCRIPTION>
<P>Five trials were identified which met the inclusion criteria, but three of these were subsequently excluded because the outcomes that were published related to infertility only. The possibility of patient overlap between two studies (<LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK>; <LINK REF="STD-Telimaa-1990" TYPE="STUDY">Telimaa 1990</LINK>) cannot be excluded as this was not clear in the reports and we have received no reply from the author. </P>
<P>Additional information was sought from every author in each of the included studies; no replies were received regarding either method of randomisation or additional data. Additional data would have been particularly useful as each of the included trials presented some, if not all, data in a graphical form only. Also, in one study only absolute values for AFS scores were provided, without standard deviations. These data had to be excluded as the authors did not respond to our requests for those standard deviations. </P>
<P>Participants were women of reproductive age. All trials specified confirmed endometriosis as an inclusion criterion (either at laparoscopy or laparotomy). In three studies the majority of women (<LINK REF="STD-Kauppila-1988" TYPE="STUDY">Kauppila 1988</LINK>; <LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK>; <LINK REF="STD-Telimaa-1990" TYPE="STUDY">Telimaa 1990</LINK>) had AFS stage one or two disease. In the one study (<LINK REF="STD-Telimaa-1987b" TYPE="STUDY">Telimaa 1987b</LINK>) only one third of women had AFS stage one and in another study ( <LINK REF="STD-Bianchi-1999" TYPE="STUDY">Bianchi 1999</LINK>) the participants had Stage III and IV disease and were being treated postoperatively. <BR/>The interventions used were the same in all trials. These were danazol (200 mg three times/day), oral medroxyprogesterone acetate (100 mg once/day + placebo twice/day) and placebo (three times/day). Duration of treatment varied from three months in one trial (<LINK REF="STD-Bianchi-1999" TYPE="STUDY">Bianchi 1999</LINK>) to six months in the other trials. In three of the trials medical therapy was used as an adjunct to surgery (<LINK REF="STD-Bianchi-1999" TYPE="STUDY">Bianchi 1999</LINK>; <LINK REF="STD-Kauppila-1988" TYPE="STUDY">Kauppila 1988</LINK>; <LINK REF="STD-Telimaa-1987b" TYPE="STUDY">Telimaa 1987b</LINK>). The extent of the surgery was not mentioned except to state that it was conservative. </P>
<P>In <LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK>, four danazol patients and five placebo patients had electrocautery at the time of diagnosis, in addition to medical therapy. </P>
<P>Three studies reported on pain <LINK REF="STD-Bianchi-1999" TYPE="STUDY">Bianchi 1999</LINK>; <LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK>; <LINK REF="STD-Telimaa-1987b" TYPE="STUDY">Telimaa 1987b</LINK> and one study reported on improvement in laparoscopic appearance(<LINK REF="STD-Kauppila-1988" TYPE="STUDY">Kauppila 1988</LINK>) . Two studies ( <LINK REF="STD-Bianchi-1999" TYPE="STUDY">Bianchi 1999</LINK>;<LINK REF="STD-Kauppila-1988" TYPE="STUDY">Kauppila 1988</LINK>) did not report on adverse events. <LINK REF="STD-Bianchi-1999" TYPE="STUDY">Bianchi 1999</LINK> did not repeat the laparoscopy. The follow up was six to 36 months in the studies. </P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-11 12:58:35 +1300" MODIFIED_BY="jane clarke">
<P>The methods used in the included trials are described in detail in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' and in the '<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>T'. One study was open (danazol versus no treatment (<LINK REF="STD-Bianchi-1999" TYPE="STUDY">Bianchi 1999</LINK>) and one of the included trials did not mention blinding (<LINK REF="STD-Telimaa-1990" TYPE="STUDY">Telimaa 1990</LINK>). Concealment of allocation was not described in any of the trials and the trials were rated as B for their attempts to control selection bias. <LINK REF="STD-Bianchi-1999" TYPE="STUDY">Bianchi 1999</LINK> described using a computer generated randomisation list. There were no reported losses to follow up in any of the trials. Also, withdrawals were few, overall, with none in three of the studies (<LINK REF="STD-Bianchi-1999" TYPE="STUDY">Bianchi 1999</LINK>; <LINK REF="STD-Kauppila-1988" TYPE="STUDY">Kauppila 1988</LINK>; <LINK REF="STD-Telimaa-1990" TYPE="STUDY">Telimaa 1990</LINK>) and nine in each of the other two studies (<LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK> (n = 59 participants) and <LINK REF="STD-Telimaa-1987b" TYPE="STUDY">Telimaa 1987b</LINK> (n = 60) due mainly to adverse effects or conception.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>
<B>(1) Symptoms </B>
<BR/>At each visit (one, three, six and 12 months), patients recorded the occurrence and severity of pelvic pain, lower back pain, defecation pain, dysuria and dyspareunia on a four-point scale (0 = symptoms absent, 1 = slight symptoms, 2 = moderate symptoms, 3 = severe symptoms). <BR/>
<B>
<I>
<BR/>Without surgery </I>
</B>
<BR/>Only one study recorded symptoms as an outcome (<LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK>). This study found a significant decrease in the levels of pelvic pain, lower back pain, defecation pain and total pain (total score for all pain symptoms) in patients treated with danazol compared to those treated with placebo, at three and six months of therapy and six months after medication. Total pain scores were reduced at six months in those patients on danazol when compared to placebo (weighted mean difference (WMD) -5.7; 95% confidence interval (CI) -7.5 to -3.8). This improvement in pain scores was still present after six months without danazol therapy. However, no significant difference was found between the two groups in terms of the levels of dysuria and dyspareunia. </P>
<P>
<B>
<I>With surgery </I>
</B>
<BR/>Two studies reported on improvement in pain symptoms (<LINK REF="STD-Bianchi-1999" TYPE="STUDY">Bianchi 1999</LINK>; <LINK REF="STD-Telimaa-1987b" TYPE="STUDY">Telimaa 1987b</LINK>). One study (<LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK> ) found a significant decrease in the levels of total pain in patients treated with danazol compared to those treated with placebo, at six months of therapy (WMD -3.4; 95% CI -4.8 to -1.8). This improvement in pain scores was still present after six months off therapy with danazol. Pelvic pain was also improved in those patients receiving six months therapy with danazol (WMD -1.1; 95% CI -1.3 to -0.8). However, no significant difference was found between the two groups in terms of the levels of lower back pain, defecation pain, dysuria and dyspareunia. </P>
<P>
<B>(2) American Fertility Society (AFS) scores </B>
<BR/>
<B>
<I>Without surgery</I>
</B> <BR/>Two studies examined the change in AFS scores at repeat laparoscopy six months after end of medication (<LINK REF="STD-Kauppila-1988" TYPE="STUDY">Kauppila 1988</LINK> ; <LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK>). However, <LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK> reported only the peritoneal deposits and not the total AFS scores while <LINK REF="STD-Kauppila-1988" TYPE="STUDY">Kauppila 1988</LINK> reported only the total AFS score, therefore, the data could not be combined. There was no significant difference in total AFS score (WMD -0.4; 95% CI -1.5 to 0.7) (<LINK REF="STD-Kauppila-1988" TYPE="STUDY">Kauppila 1988</LINK>). <LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK> found that danazol caused a decrease in peritoneal AFS scores (WMD -1.4; 95% CI -2.2 to -0.6). </P>
<P>
<B>
<I>With surgery </I>
</B>
<BR/>Two studies examined the change in AFS scores at laparoscopy six months after the end of medication (<LINK REF="STD-Kauppila-1988" TYPE="STUDY">Kauppila 1988</LINK>;<LINK REF="STD-Telimaa-1987b" TYPE="STUDY">Telimaa 1987b</LINK>). However, <LINK REF="STD-Telimaa-1987b" TYPE="STUDY">Telimaa 1987b</LINK> only reported the peritoneal deposits and not the total AFS scores while <LINK REF="STD-Kauppila-1988" TYPE="STUDY">Kauppila 1988</LINK> reported only the total AFS score; data, therefore, could not be combined. There was a significant difference in the total AFS score at 12 months (six months after the end of therapy) in those patients who received danazol (WMD -3.5; 95% CI -5.2 to -1.7). A difference was reported in peritoneal AFS scores for patients treated with danazol (WMD -2.1; CI -3.9 to -0.2). There was no difference in complete resolution of deposits between danazol therapy and placebo (WMD 1.72; 95% CI 0.44 to 6.74).</P>
<P>
<B>
<I>With surgery </I>
</B>
<BR/>There were no studies that included hormonal data. </P>
<P>
<B>(5) Patient satisfaction with treatment</B> <BR/>
<B>
<I>With surgery </I>
</B>
<BR/>Only one study looked at patient satisfaction with treatment (<LINK REF="STD-Telimaa-1987b" TYPE="STUDY">Telimaa 1987b</LINK>). This study found that satisfaction at six months was significantly higher in those patients receiving danazol (OR 9.9; 95% CI 2.6 to 37.8). <BR/>
<B>
<BR/>(6) Adverse effects </B>
<BR/>
<B>
<I>Without surgery</I>
</B> <BR/>Only one study looked at adverse effects (<LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK>). This study found a significant increase in the following symptoms at six months: acne (OR 10.8; 95% CI 2.7 to 42.8), muscle cramps (OR 9.7; 95% CI 1.7 to 55.3) and oedema (OR 7.11; 95% CI 1.5 to 31.6). Vaginal spotting occurred more often in patients treated with danazol, at one and three months (OR 14.0; 95% CI 3.3 to 59.7) but did not persist at six months. There was a 5% increase in weight at six months in patients treated with danazol compared to those treated with placebo. However, no significant difference was found between the two groups in terms of the occurrence of greasy hair, hot flushes, sweating, decreased breast size, dizziness, decreased libido, nausea, nervousness, hirsutism, headache, insomnia, skin rash and depression. </P>
<P>
<B>
<I>With surgery </I>
</B>
<BR/>Only one study looked at adverse effects (<LINK REF="STD-Telimaa-1987b" TYPE="STUDY">Telimaa 1987b</LINK>). This study found a significant increase in the following symptoms at six months: acne (OR 8.9; 95% CI 2.16 to 36.7), weight gain (WMD 3.0; 95% CI 1.3 to 4.6) and spotting (OR 8.9; 95% CI 2.6 to 36.7). However, no significant difference was found between the two groups in terms of the occurrence of muscle cramps, oedema, greasy hair, hot flushes, sweating, decreased breast size, dizziness, decreased libido, nausea, nervousness, hirsutism, headache, insomnia, skin rash and depression.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>The included trials have shown that six months therapy with danazol was significantly better than placebo at relieving painful symptoms. The improvement was still present six months after treatment was stopped. Danazol also had a significant effect on AFS scores, CA-125 levels and free androgen index (FAI). Patient satisfaction was significantly greater with six months of danazol than with placebo. However, this positive effect may be offset by the fact that danazol also caused a significant occurrence of side effects not experienced by those taking placebo. </P>
<P>There were several inadequacies in the available trials. The method of randomisation was only specified in one trial; therefore, the results may not be valid as the method of randomisation may not have been adequate. None of the trials that used blinding were truly double blind as women who received placebo tablets continued menstruating while women who received danazol became amenorrhoeic, making identification of therapy possible. In addition, most of the trials looked at different outcomes thus making statistical pooling of results between trials impossible. Furthermore, the measurement of pain was inadequate as none of the trials used visual analogue scales or other recognised methods for measuring pain. Finally, there was insufficient power in the study design (even when data are combined) to detect, with significance at the 5% level, a difference between danazol and placebo in improvement of pain of 30%. A total of at least 70 participants in each treatment group would be required to show such a difference. It is noted that there is uncertainty about duplication of patients within the included trials and, therefore, the results should be interpreted with caution. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Danazol is an effective therapy for the symptoms and signs of endometriosis but also causes unpleasant side effects such as weight gain and acne. Since its introduction in the 1970s it has become the gold standard for comparing both the medical and surgical treatment of endometriosis in spite of paucity of evidence of its efficacy (in the form of randomised controlled trials). Other treatments are now available which have different side-effect profiles and should also be considered (See a Cochrane review on progestogens: <LINK REF="REF-Prentice-2000" TYPE="REFERENCE">Prentice 2000</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The included trials were mostly conducted in the late eighties. All of the early literature on which the use of danazol was recommended used data from non-controlled non-randomised clinical trials. The limited number of randomised controlled trials of danazol versus placebo or no treatment highlights the need for more well-designed studies to investigate the overall effects of the drug on women. The lack of data on patient satisfaction, compliance and need for future therapy highlights the need for new research to incorporate these outcomes. The side-effect profile and the availability of other treatments such as gonadotrophin releasing hormone agonist and progestogens makes danazol an unpopular choice for the management of the endometriosis and it is unlikely that further studies will be undertaken in the future.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors wish to thank the following people: <BR/>Dr Antti Kauppila for providing additional information about randomisation for all of the included studies (<LINK REF="STD-Kauppila-1988" TYPE="STUDY">Kauppila 1988</LINK>; <LINK REF="STD-Telimaa-1987a" TYPE="STUDY">Telimaa 1987a</LINK>; <LINK REF="STD-Telimaa-1987b" TYPE="STUDY">Telimaa 1987b</LINK>; <LINK REF="STD-Telimaa-1990" TYPE="STUDY">Telimaa 1990</LINK>):<BR/>Dr Tahir Mahmood for providing additional information for two trials (<LINK REF="STD-Mahmood-1990" TYPE="STUDY">Mahmood 1990</LINK>; <LINK REF="STD-Mahmood-1991" TYPE="STUDY">Mahmood 1991</LINK>).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>A new search for further randomised controlled trials in July 2001 did not identify any further trials. The outcomes were revised and only outcomes that were considered clinically relevant were included.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-11 13:00:22 +1300" MODIFIED_BY="jane clarke">
<STUDIES MODIFIED="2008-11-11 13:00:22 +1300" MODIFIED_BY="jane clarke">
<INCLUDED_STUDIES MODIFIED="2008-11-11 13:00:22 +1300" MODIFIED_BY="jane clarke">
<STUDY DATA_SOURCE="PUB" ID="STD-Bianchi-1999" MODIFIED="2008-11-11 13:00:22 +1300" MODIFIED_BY="jane clarke" NAME="Bianchi 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Bianchi S, Agnoli B, Sgherzi MR, Candiani M, Busacca M</AU>
<TI>Effect of three-month treatment with danazol after laparoscopic surgery for stage III-IV endometriosis: a randomized clinical trial</TI>
<SO>Fertility and Sterility</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-11-11 13:00:22 +1300" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bianchi S, Busacca M, Agnoli B, Candiani M, Calia C, Vignali M</AU>
<TI>Effect of three-month treatment with danazol after laparoscopic surgery for stage III-IV endometriosis: a randomized clinical trial</TI>
<SO>Fertility and Sterility</SO>
<YR>1999</YR>
<VL>Suppl</VL>
<PG>22-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kauppila-1988" NAME="Kauppila 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kauppila A, Telimaa S, Ronnberg L, Vuori J</AU>
<TI>Placebo-controlled study on serum concentrations of CA-125 before and after treatment of endometriosis with danazol or high-dose medroxyprogesterone acetate alone or after surgery</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1988</YR>
<VL>49</VL>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Telimaa-1987a" NAME="Telimaa 1987a" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Telimaa S, Puolakka J, Ronnberg L, Kauppila A</AU>
<TI>Placebo-controlled comparison of danazol and medroxyprogesterone acetate in the treatment of endometriosis</TI>
<SO>Gynecological Endocrinology</SO>
<YR>1987</YR>
<VL>1</VL>
<PG>13-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Telimaa-1987b" NAME="Telimaa 1987b" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Telimaa S, Ronnberg L, Kauppila A</AU>
<TI>Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery</TI>
<SO>Gynecological Endocrinology</SO>
<YR>1987</YR>
<VL>1</VL>
<PG>363-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Telimaa-1990" NAME="Telimaa 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Telimaa S, Apter D, Reinila M, Ronnberg L, Kauppila A</AU>
<TI>Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate</TI>
<SO>European Journal of Obstetrics Gynecology and Reproductive Biology</SO>
<YR>1990</YR>
<VL>36</VL>
<PG>97-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bayer-1988" NAME="Bayer 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bayer S, Seibel M, Saffan D, Berger M, Taymor M</AU>
<TI>Efficacy of danazol treatment for minimal endometriosis in infertile women. A prospective, randomized study</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1988</YR>
<VL>33</VL>
<PG>179-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmood-1990" NAME="Mahmood 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mamood TA</AU>
<TI>The impact of treatment on the natural history of endometriosis</TI>
<SO>Human Reproduction</SO>
<YR>1990</YR>
<VL>5</VL>
<PG>965-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmood-1991" NAME="Mahmood 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mamood TA</AU>
<TI>Peritoneal fluid volume and sex steroids in the preovulatory period in mild endometriosis</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1991</YR>
<VL>98</VL>
<PG>179-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morgante-1999" NAME="Morgante 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morgante G, Ditto A, La Marca A, De Leo V</AU>
<TI>Low dose danazol after combined surgical and medical therapy reduces the incidence of pelvic pain in women with moderate and severe endometriosis</TI>
<SO>Human Reproduction</SO>
<YR>1999</YR>
<VL>14(9)</VL>
<PG>2371-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nezhat-1996" NAME="Nezhat 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nezhat CH, Nezhat F, Borhan S, Seidman DS, and Nezhat CR.</AU>
<TI>Is hormonal treatment efficacious in the management of ovarian cysts in women with histories of endometriosis?</TI>
<SO>Human Reproduction</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>874-7.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seibel-1982" NAME="Seibel 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seibel M, Berger M, Weinstein F, Taymor M</AU>
<TI>The effectiveness of danazol on subsequent fertility in minimal endometriosis</TI>
<SO>Fertility and Sterility</SO>
<YR>1982</YR>
<VL>38</VL>
<PG>534-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Telimaa-1988" NAME="Telimaa 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Telimaa S</AU>
<TI>Danazol and medroxyprogesterone acetate inefficacious in the treatment of infertility in endometriosis</TI>
<SO>Fertility and Sterility</SO>
<YR>1988</YR>
<VL>50</VL>
<PG>872-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Barbieri-1990" NAME="Barbieri 1990" TYPE="JOURNAL_ARTICLE">
<AU>Barbieri RL</AU>
<TI>Endometriosis 1990 - current treatment approaches</TI>
<SO>Drugs</SO>
<YR>1990</YR>
<VL>39</VL>
<NO>4</NO>
<PG>502-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hughes-2007" NAME="Hughes 2007" TYPE="COCHRANE_REVIEW">
<AU>Hughes E, Fedorkow D, Collins J, Vandekerckhove P</AU>
<TI>Ovulation suppression for endometriosis (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLaren-1996" NAME="McLaren 1996" TYPE="JOURNAL_ARTICLE">
<AU>McLaren J, Prentice A</AU>
<TI>New aspects of pathogenesis of endometriosis</TI>
<SO>Current Opinion in Obstetrics &amp; Gynecology</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>85-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prentice-2000" NAME="Prentice 2000" TYPE="COCHRANE_REVIEW">
<AU>Prentice A, Deary AJ, Bland E</AU>
<TI>Progestagens and anti-progestagens for pain associated with endometriosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rock-1992" NAME="Rock 1992" TYPE="JOURNAL_ARTICLE">
<AU>Rock JA, Markham SM</AU>
<TI>Pathogenesis of endometriosis</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>1264-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yap-2004" NAME="Yap 2004" NOTES="&lt;p&gt;C Yap, S Furness, C Farquhar. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database of Systematic Reviews 2004, Issue 3. &lt;br&gt;&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>C Yap, S Furness, C Farquhar. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD003678. DOI: 10.1002/14651858.CD003678.pub2</AU>
<TI>Pre and post operative medical therapy for endometriosis surgery</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>3</NO>
<PB>Wiley</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bianchi-1999">
<CHAR_METHODS>
<P>Randomised, placebo-controlled open trial<BR/>Method of randomisation: not specified<BR/>Exclusions post randomisation: none<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy<BR/>77 women &lt;41 yrs old with moderate or severe endometriosis who had undergone laparoscopic surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Danazol 600 mg/day for 3 months versus no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pelvic pain recurrence, pregnancy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kauppila-1988">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double blind trial<BR/>Method of randomisation: not specified<BR/>Exclusions postrandomisation: none<BR/>Unusual study design: factorial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Finland<BR/>87 patients divided into two groups of 47 and 40 to undergo laparoscopy or laparotomy respectively. Patients in each group were then randomised to one of 3 intervention groups (medroxyprogesterone acetate (MPA), danazol or placebo)<BR/>post laparoscopy group:<BR/> MPA group: n = 16, age = 32.5 +/- 5.9 SD years<BR/> danazol group: n = 17, age = 31.1 +/- 5.6 SD years<BR/> placebo group: n = 14, age= 31.9 +/- 6.0 SD years<BR/>Post laparotomy group:<BR/> MPA group: n = 13, age = 29.5 +/- 5.8 SD years<BR/> danazol group: n = 15, age = 32.1 +/- 6.7 SD years<BR/> placebo group: n = 12, age= 28.2 +/- 5.6 SD years<BR/>Inclusion criteria: endometriosis confirmed at laparoscopy or laparotomy <BR/>AFS scores: 72 of 87 women had stage I and II<BR/>Exclusion criteria: none</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatments: MPA 100 mg x 1/day + placebo x 2/day; danazol 200 mg x 3/day<BR/>Control: placebo x 3/day<BR/>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AFS scores<BR/>Levels of CA-125</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Telimaa-1987a">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double blind trial<BR/>Method of randomisation: not specified<BR/>Exclusions post randomisation: x 4 MPA (x 1 hot flushes, x 1 nervousness, x 1 psychological, x 1 conception); x 2 danazol (x 1 skin rash, x 1 conception); x 3 placebo (x 3 conceptions)<BR/>Losses to follow up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Finland<BR/>59 patients randomised to one of 3 intervention groups (MPA, danazol or placebo)<BR/>MPA group: n = 20, age = 32.2 +/- 5.4 SD years<BR/>danazol group: n = 20, age = 31.4+/- 5.2 SD years<BR/>placebo group: n = 19, age = 32.4 +/- 5.7 SD years<BR/>Inclusion criteria: laparoscopically confirmed endometriosis, no previous surgical and/or medical treatment for endometriosis<BR/>AFS scores: all women had stage I or II disease<BR/>Exclusion criteria: none stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatments: MPA 100 mg/day; danazol 200 mg 3 x/day<BR/>Control: placebo<BR/>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AFS scores (peritoneal implants component)<BR/>Symptoms <BR/>Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Telimaa-1987b">
<CHAR_METHODS>
<P>Randomised, placebo-controlled double blind trial<BR/>Method of randomisation: not specified<BR/>Exclusions post randomisation: x 3 MPA (x 3 conceptions), x 2 danazol (x 2 conceptions), x 4 placebo (x 3 conceptions, x 1 insomnia/nervousness/depression)<BR/>Losses to follow up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Finland<BR/>60 patients randomised to one of 3 intervention groups (MPA, danazol or placebo)<BR/>MPA group: n = 20, age = 29.4 +/- 5.4 SD years<BR/>danazol group: n = 20, age = 31.5 +/- 6.0 SD years<BR/>placebo group: n = 20 age = 29.1 +/- 5.9 SD years<BR/>Inclusion criteria: recent conservative surgery for endometriosis, no previous surgical and/or medical treatment for endometriosis<BR/>AFS scores: 11 of 33 women had stage I or II disease<BR/>Exclusion criteria: not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatments: MPA 100 mg/day; danazol 200 mg 3 x/day<BR/>Control: placebo<BR/>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>AFS scores (peritoneal implants component)<BR/>Symptoms<BR/>Adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Telimaa-1990">
<CHAR_METHODS>
<P>Randomised, placebo-controlled trial<BR/>Blinding: unclear<BR/>Method of randomisation: not specified<BR/>Exclusions post randomisation: none<BR/>Losses to follow-up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Finland<BR/>87 patients divided into two groups of 33 and 54 evaluated for hormonal parameters and biochemical parameters respectively. Each group of patients was randomised to one of 3 intervention groups (MPA, danazol or placebo)<BR/>Hormonal group:<BR/> MPA: n = 11, age = 31.1 +/- 6.3 SD years<BR/> danazol: n = 11, age = 30.7 +/- 4.6 SD years<BR/> placebo: n = 11, age = 32.8 +/- 5.7 SD years<BR/>Biochemical group:<BR/> MPA: n = 18, age = 29.8 +/- 5.7 SD years<BR/> danazol: n = 18, age = 31.5 +/- 6.0 SD years<BR/> placebo: n = 18, age = 29.6 +/- 6.0 SD years<BR/>Inclusion criteria: endometriosis confirmed by laparoscopy or laparotomy<BR/>AFS scores: all women had stage I or II disease<BR/>Exclusion criteria: none</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatments: MPA 100 mg/day; danazol 200 mg 3 x/day<BR/>Control: placebo<BR/>Duration: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Levels of hormonal parameters<BR/>-LH<BR/>-FSH<BR/>-prolactin<BR/>-progesterone<BR/>-oestradiol<BR/>-testosterone/free androgen index<BR/>-sex-hormone binding globulin<BR/>Levels of biochemical parameters<BR/>-albumin<BR/>-ALT<BR/>-AST<BR/>-ALP<BR/>-GGT<BR/>-bilirubin (total and conjugated)<BR/>-creatinine<BR/>-sodium<BR/>-potassium<BR/>-white cell count<BR/>-platelets<BR/>Haemoglobin</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bayer-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes published relate to infertility only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahmood-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>No outcomes of interest, unclear randomisation process.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahmood-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Did not include outcomes of interest to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morgante-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment period was post opertative and included surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nezhat-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Women had oviarian cysts and endometriosis was not confirmed</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Seibel-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes published relate to infertility only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Telimaa-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcomes published relate to infertility only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bianchi-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kauppila-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Telimaa-1987a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Telimaa-1987b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Telimaa-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-11 13:01:02 +1300" MODIFIED_BY="jane clarke">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-11 13:01:02 +1300" MODIFIED_BY="jane clarke" NO="1">
<TITLE MODIFIED="2008-11-11 12:53:05 +1300" MODIFIED_BY="jane clarke">Table of included studies risk of bias</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Concealed allocation</P>
</TH>
<TH>
<P>Method of randomisat</P>
</TH>
<TH>
<P>Losses to followup</P>
</TH>
<TH>
<P>Post random exclus</P>
</TH>
<TH>
<P>Intention to treat</P>
</TH>
<TH>
<P>Blinding</P>
</TH>
</TR>
<TR>
<TD>
<P>Bianci 1999</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Computer generated list</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>Open study</P>
</TD>
</TR>
<TR>
<TD>
<P>Kaupilla 1988</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>Double blind</P>
</TD>
</TR>
<TR>
<TD>
<P>Telimaa 1987a</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>9 - 4 in the MPA group and 2 in the danazol group and 3 in the placebo group (5 for pregnancies)</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>Double blind</P>
</TD>
</TR>
<TR>
<TD>
<P>Telimaa 1987b</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>9 - 3 in the MPA group, 2 in the danazol group and 4 in the placebo group, 8 for pregnancies</P>
</TD>
<TD>
<P>no</P>
</TD>
<TD>
<P>Double blind</P>
</TD>
</TR>
<TR>
<TD>
<P>Telimaa 1990</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>Not stated</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>yes</P>
</TD>
<TD>
<P>Unclear</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-11 12:54:54 +1300" MODIFIED_BY="jane clarke">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-11 12:54:47 +1300" MODIFIED_BY="jane clarke" NO="1">
<NAME>Danazol versus placebo - no surgery</NAME>
<CONT_OUTCOME CHI2="4.078937178402942" CI_END="-4.924279419278295" CI_START="-6.973553850632475" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.948916634955385" ESTIMABLE="YES" I2="50.967619442889394" I2_Q="50.967619442889394" ID="CMP-001.01" NO="1" P_CHI2="0.130098085703085" P_Q="0.130098085703085" P_Z="5.301881946686077E-30" Q="4.078937178402942" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="54" TOTAL_2="51" UNITS="" WEIGHT="300.0" Z="11.379307888830636">
<NAME>Total pain</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.2900381358088078" CI_START="-6.609961864191193" DF="0.0" EFFECT_SIZE="-4.95" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="1.0" P_Z="5.077711060596227E-9" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="5.844605188083902">
<NAME>Three months of treatment</NAME>
<CONT_DATA CI_END="-3.2900381358088078" CI_START="-6.609961864191193" EFFECT_SIZE="-4.95" ESTIMABLE="YES" MEAN_1="2.25" MEAN_2="7.2" ORDER="96632" SD_1="2.54" SD_2="2.47" SE="0.8469348810920811" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.8941439485490794" CI_START="-7.505856051450921" DF="0.0" EFFECT_SIZE="-5.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="6.154357958622862E-10" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="6.186425935169249">
<NAME>Six months of treatment</NAME>
<CONT_DATA CI_END="-3.89414394854908" CI_START="-7.5058560514509205" EFFECT_SIZE="-5.7" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="6.7" ORDER="96633" SD_1="2.97" SD_2="2.47" SE="0.9213720587190798" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.573874576801043E-31" CI_END="-5.619991794661658" CI_START="-9.380008205338344" DF="0.0" EFFECT_SIZE="-7.500000000000001" ESTIMABLE="YES" I2="100.0" ID="CMP-001.01.03" NO="3" P_CHI2="0.0" P_Z="5.325682118458148E-15" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="7.818971131248288">
<NAME>Six months after stopping treatment</NAME>
<CONT_DATA CI_END="-5.619991794661657" CI_START="-9.380008205338344" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="10.5" ORDER="96634" SD_1="2.54" SD_2="3.09" SE="0.9592054854923906" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.752186679224282" CI_END="-0.8550139796970087" CI_START="-1.1621464416291947" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0085802106631017" ESTIMABLE="YES" I2="87.30335006353232" I2_Q="87.30335006353232" ID="CMP-001.02" NO="2" P_CHI2="3.797150571875907E-4" P_Q="3.797150571875907E-4" P_Z="6.428940098395678E-38" Q="15.752186679224282" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="54" TOTAL_2="51" UNITS="" WEIGHT="300.0" Z="12.872497267032404">
<NAME>Pelvic pain</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3996882925316906" CI_START="-0.9003117074683097" DF="0.0" EFFECT_SIZE="-0.6500000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="1.0" P_Z="3.5889426217955977E-7" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="5.089560543676631">
<NAME>Three months of treatment</NAME>
<CONT_DATA CI_END="-0.3996882925316906" CI_START="-0.9003117074683097" EFFECT_SIZE="-0.6500000000000001" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.35" ORDER="96635" SD_1="0.34" SD_2="0.41" SE="0.12771240157611893" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.1249881000129456" CI_START="-1.6750118999870547" DF="0.0" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="1.0" P_Z="1.9109554826397918E-23" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="9.97756671069594">
<NAME>Six months of treatment</NAME>
<CONT_DATA CI_END="-1.1249881000129456" CI_START="-1.6750118999870547" EFFECT_SIZE="-1.4000000000000001" ESTIMABLE="YES" MEAN_1="0.45" MEAN_2="1.85" ORDER="96636" SD_1="0.42" SD_2="0.41" SE="0.14031477218781224" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.7749881000129455" CI_START="-1.3250118999870546" DF="0.0" EFFECT_SIZE="-1.05" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.03" NO="3" P_CHI2="1.0" P_Z="7.254815332345034E-14" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="7.483175033021956">
<NAME>Six months after stopping treatment</NAME>
<CONT_DATA CI_END="-0.7749881000129455" CI_START="-1.3250118999870546" EFFECT_SIZE="-1.05" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.85" ORDER="96637" SD_1="0.42" SD_2="0.41" SE="0.14031477218781224" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3834329632792468" CI_END="-0.8005824628206221" CI_START="-1.300487512564921" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0505349876927714" ESTIMABLE="YES" I2="27.716049382715962" I2_Q="27.716049382715962" ID="CMP-001.03" NO="3" P_CHI2="0.23951745050732054" P_Q="0.23951745050732054" P_Z="1.7568875497724366E-16" Q="1.3834329632792468" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="34" UNITS="" WEIGHT="200.0" Z="8.237607287344844">
<NAME>Low back pain</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.5458816888377964" CI_START="-1.2541183111622038" DF="0.0" EFFECT_SIZE="-0.9000000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="1.0" P_Z="6.316034208290088E-7" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="4.9812944727336195">
<NAME>Six months of treatment</NAME>
<CONT_DATA CI_END="-0.5458816888377964" CI_START="-1.2541183111622038" EFFECT_SIZE="-0.9000000000000001" ESTIMABLE="YES" MEAN_1="0.45" MEAN_2="1.35" ORDER="96638" SD_1="0.64" SD_2="0.41" SE="0.1806759276983882" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8471424374854999" CI_START="-1.5528575625145" DF="0.0" EFFECT_SIZE="-1.2" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="1.0" P_Z="2.6384370810738585E-11" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="6.665456635498397">
<NAME>Six months after stopping treatment</NAME>
<CONT_DATA CI_END="-0.8471424374854999" CI_START="-1.5528575625145" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.7" ORDER="96639" SD_1="0.42" SD_2="0.62" SE="0.18003267677253026" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.14957546059658827" CI_END="-0.4950123788317177" CI_START="-0.9505606437560714" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7227865112938946" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.6989415476284729" P_Q="0.6989415476284729" P_Z="4.988209762413528E-10" Q="0.14957546059658827" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="34" UNITS="" WEIGHT="200.0" Z="6.219475035790671">
<NAME>Defaecation pain</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.43965159247560753" CI_START="-1.1003484075243926" DF="0.0" EFFECT_SIZE="-0.77" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="1.0" P_Z="4.914003991698288E-6" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="4.568426042690721">
<NAME>6 months of treatment</NAME>
<CONT_DATA CI_END="-0.43965159247560753" CI_START="-1.1003484075243926" EFFECT_SIZE="-0.77" ESTIMABLE="YES" MEAN_1="0.02" MEAN_2="0.79" ORDER="96640" SD_1="0.64" SD_2="0.31" SE="0.16854820299257464" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3655203049898442" CI_START="-0.9944796950101557" DF="0.0" EFFECT_SIZE="-0.6799999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="1.0" P_Z="2.2548604372546765E-5" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="4.238033585742941">
<NAME>6 months after stopping treatment</NAME>
<CONT_DATA CI_END="-0.3655203049898442" CI_START="-0.9944796950101557" EFFECT_SIZE="-0.6799999999999999" ESTIMABLE="YES" MEAN_1="0.2" MEAN_2="0.88" ORDER="96641" SD_1="0.59" SD_2="0.33" SE="0.1604517723237424" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="4.724529440224933" CI_END="20.628137024084587" CI_START="2.9333470199902676" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="7.778784240969115" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="5" I2="36.50161274352921" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="1.3144600075808173" LOG_CI_START="0.46736344380290906" LOG_EFFECT_SIZE="0.8909117256918633" METHOD="MH" MODIFIED="2008-11-11 12:54:38 +1300" MODIFIED_BY="jane clarke" NO="5" P_CHI2="0.1931161253507946" P_Q="0.0" P_Z="3.744864482038669E-5" Q="0.0" RANDOM="NO" SCALE="437.9518760783689" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="72" TOTAL_2="68" WEIGHT="400.0" Z="4.122682042228863">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="118.31827339140698" CI_START="1.384739612096968" DF="0.0" EFFECT_SIZE="12.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="2.073051823412301" LOG_CI_START="0.14136811588343548" LOG_EFFECT_SIZE="1.1072099696478683" NO="1" P_CHI2="1.0" P_Z="0.02465028396112806" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="2.246839537317038">
<NAME>Oedema at six months</NAME>
<DICH_DATA CI_END="118.31827339140698" CI_START="1.384739612096968" EFFECT_SIZE="12.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="2.073051823412301" LOG_CI_START="0.14136811588343548" LOG_EFFECT_SIZE="1.1072099696478683" ORDER="96642" O_E="0.0" SE="1.1346805717910218" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" VAR="1.2875" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="234.1741645772121" CI_START="2.6995431645820376" DF="0.0" EFFECT_SIZE="25.142857142857142" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="2.3695389795473236" LOG_CI_START="0.43129027605246234" LOG_EFFECT_SIZE="1.400414627799893" NO="2" P_CHI2="1.0" P_Z="0.00462276933329487" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="2.832208507568474">
<NAME>Acne at six months</NAME>
<DICH_DATA CI_END="234.1741645772123" CI_START="2.6995431645820362" EFFECT_SIZE="25.142857142857142" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" LOG_CI_END="2.3695389795473236" LOG_CI_START="0.4312902760524622" LOG_EFFECT_SIZE="1.400414627799893" ORDER="96643" O_E="0.0" SE="1.138536882918702" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" VAR="1.2962662337662338" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8081594835214285E-32" CI_END="9.053600283170688" CI_START="0.3558324488893898" DF="0.0" EFFECT_SIZE="1.7948717948717947" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="100.0" ID="CMP-001.05.03" LOG_CI_END="0.9568213164630388" LOG_CI_START="-0.4487544504875235" LOG_EFFECT_SIZE="0.2540334329877576" NO="3" P_CHI2="0.0" P_Z="0.47866028875662225" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="0.7084589692454288">
<NAME>Vaginal spotting at six months</NAME>
<DICH_DATA CI_END="9.053600283170688" CI_START="0.3558324488893898" EFFECT_SIZE="1.794871794871795" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.9568213164630388" LOG_CI_START="-0.4487544504875235" LOG_EFFECT_SIZE="0.25403343298775766" ORDER="96644" O_E="0.0" SE="0.8256421632190193" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" VAR="0.6816849816849817" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="353.5502778368383" CI_START="0.9368964494290837" DF="0.0" EFFECT_SIZE="18.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="2.548451182869662" LOG_CI_START="-0.028308406899512882" LOG_EFFECT_SIZE="1.2600713879850747" NO="4" P_CHI2="1.0" P_Z="0.055250705182575875" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="17" WEIGHT="100.0" Z="1.9168994641222061">
<NAME>Muscle cramps at six months</NAME>
<DICH_DATA CI_END="353.5502778368383" CI_START="0.936896449429084" EFFECT_SIZE="18.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.548451182869662" LOG_CI_START="-0.028308406899512726" LOG_EFFECT_SIZE="1.2600713879850747" ORDER="96645" O_E="0.0" SE="1.5136013381960953" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="18" TOTAL_2="17" VAR="2.2909890109890108" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.7821386130239087" CI_START="-1.5821386130239086" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.5072072071697453" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="0.663192611406701">
<NAME>AFS scores, total - 12 months (six months after stopping treatment)</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Danazol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7821386130239087" CI_START="-1.5821386130239086" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="2.0" ORDER="96646" SD_1="1.5" SD_2="1.8" SE="0.6031430283150441" STUDY_ID="STD-Kauppila-1988" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3569463169085285" CI_START="-4.156946316908528" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.09894564137804794" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="14" UNITS="" WEIGHT="100.0" Z="1.6499867731577196">
<NAME>AFS scores, total - change in</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Danazol</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3569463169085285" CI_START="-4.156946316908528" EFFECT_SIZE="-1.9" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="0.2" ORDER="96647" SD_1="3.7" SD_2="2.7" SE="1.1515243824432657" STUDY_ID="STD-Kauppila-1988" TOTAL_1="17" TOTAL_2="14" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="30.281002028640366" CI_START="0.825600156043532" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="1.4811702423045525" LOG_CI_START="-0.08323023363251493" LOG_EFFECT_SIZE="0.6989700043360189" METHOD="MH" MODIFIED="2008-11-11 12:54:47 +1300" MODIFIED_BY="jane clarke" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.0798747140230991" Q="0.0" RANDOM="NO" SCALE="36.37524768419769" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="1.7514134722463646">
<NAME>Total or partial resoultion of peritoneal endometriotic implants</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="30.281002028640366" CI_START="0.825600156043532" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.4811702423045525" LOG_CI_START="-0.08323023363251493" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="96648" O_E="0.0" SE="0.9189365834726815" STUDY_ID="STD-Telimaa-1987a" TOTAL_1="15" TOTAL_2="17" VAR="0.8444444444444444" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-11-11 12:54:54 +1300" MODIFIED_BY="jane clarke" NO="2">
<NAME>Danazol versus placebo - post surgery</NAME>
<CONT_OUTCOME CHI2="5.89916067723239" CI_END="-1.8295617958972428" CI_START="-3.4730595042667534" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.651310650081998" ESTIMABLE="YES" I2="66.09687192079829" I2_Q="66.09687192079829" ID="CMP-002.01" NO="1" P_CHI2="0.05236177466380343" P_Q="0.05236177466380343" P_Z="2.5541322871594553E-10" Q="5.89916067723239" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="54" TOTAL_2="48" UNITS="" WEIGHT="300.0" Z="6.323675852451949">
<NAME>Total pain</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8145274128207844" CI_START="-3.5854725871792157" DF="0.0" EFFECT_SIZE="-2.2" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="1.0" P_Z="0.0018567459229214647" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="3.112238239781469">
<NAME>3 months of treatment</NAME>
<CONT_DATA CI_END="-0.8145274128207844" CI_START="-3.5854725871792157" EFFECT_SIZE="-2.2" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="3.2" ORDER="96649" SD_1="2.12" SD_2="2.0" SE="0.7068867581790516" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-2.6898028462204033" CI_START="-5.710197153779597" DF="0.0" EFFECT_SIZE="-4.2" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="1.0" P_Z="5.013139835363755E-8" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="5.450843761999046">
<NAME>6 months of treatment</NAME>
<CONT_DATA CI_END="-2.6898028462204033" CI_START="-5.710197153779597" EFFECT_SIZE="-4.2" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="4.8" ORDER="96650" SD_1="1.27" SD_2="2.84" SE="0.7705229104676612" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.41519763694294576" CI_START="-3.184802363057054" DF="0.0" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.03" NO="3" P_CHI2="1.0" P_Z="0.01084639160673659" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="2.5476091507989045">
<NAME>6 months or more after treatment</NAME>
<CONT_DATA CI_END="-0.41519763694294576" CI_START="-3.184802363057054" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="2.5" MEAN_2="4.3" ORDER="96651" SD_1="1.27" SD_2="2.56" SE="0.7065448008127692" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.387205387205388" CI_END="-0.5374384398455997" CI_START="-0.8558948934877341" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6966666666666669" ESTIMABLE="YES" I2="83.85430823593369" I2_Q="83.85430823593369" ID="CMP-002.02" NO="2" P_CHI2="0.0020424659756926866" P_Q="0.0020424659756926866" P_Z="9.876543458813527E-18" Q="12.387205387205388" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="54" TOTAL_2="48" UNITS="" WEIGHT="300.0" Z="8.575373871560183">
<NAME>Pelvic pain</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.24420862114681013" CI_START="-0.7957913788531898" DF="0.0" EFFECT_SIZE="-0.52" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.01" NO="1" P_CHI2="1.0" P_Z="2.194725490650966E-4" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="3.6954790834972475">
<NAME>3 months of treatment</NAME>
<CONT_DATA CI_END="-0.24420862114681013" CI_START="-0.7957913788531898" EFFECT_SIZE="-0.52" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="1.22" ORDER="96652" SD_1="0.42" SD_2="0.4" SE="0.1407124727947029" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.8242086211468103" CI_START="-1.37579137885319" DF="0.0" EFFECT_SIZE="-1.1" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" NO="2" P_CHI2="1.0" P_Z="5.394284119416623E-15" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="7.817359599705716">
<NAME>6 months of treatment</NAME>
<CONT_DATA CI_END="-0.8242086211468103" CI_START="-1.37579137885319" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="0.45" MEAN_2="1.55" ORDER="96653" SD_1="0.42" SD_2="0.4" SE="0.1407124727947029" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1942086211468103" CI_START="-0.74579137885319" DF="0.0" EFFECT_SIZE="-0.4700000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.03" NO="3" P_CHI2="1.0" P_Z="8.373479212052403E-4" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="3.340144556237898">
<NAME>6 months after treatment</NAME>
<CONT_DATA CI_END="-0.1942086211468103" CI_START="-0.74579137885319" EFFECT_SIZE="-0.4700000000000002" ESTIMABLE="YES" MEAN_1="1.15" MEAN_2="1.62" ORDER="96654" SD_1="0.42" SD_2="0.4" SE="0.1407124727947029" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0516431894237477" CI_START="0.20476076157563616" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6481481481481481" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.3121018328829836" LOG_CI_START="-0.6887532638283693" LOG_EFFECT_SIZE="-0.1883257154726929" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.4607621040122807" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="0.7375925264347585">
<NAME>Moderate or severe pain 6 months or more after followup</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0516431894237472" CI_START="0.2047607615756362" EFFECT_SIZE="0.6481481481481481" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3121018328829835" LOG_CI_START="-0.6887532638283693" LOG_EFFECT_SIZE="-0.1883257154726929" ORDER="96655" O_E="0.0" SE="0.5879072381208795" STUDY_ID="STD-Bianchi-1999" TOTAL_1="31" TOTAL_2="29" VAR="0.3456349206349206" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="90.58552511438657" CI_START="3.8810008503683733" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="18.75" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="1.9570588062289311" LOG_CI_START="0.588943737898544" LOG_EFFECT_SIZE="1.2730012720637376" METHOD="MH" MODIFIED="2008-11-11 12:54:54 +1300" MODIFIED_BY="jane clarke" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="2.6489953111064697E-4" Q="0.0" RANDOM="NO" SCALE="204.1915759763056" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="32" WEIGHT="200.0" Z="3.6474075949817295">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="173.94210213215067" CI_START="2.021146667141599" DF="0.0" EFFECT_SIZE="18.75" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="2.240404714323651" LOG_CI_START="0.30559782980382405" LOG_EFFECT_SIZE="1.2730012720637376" NO="1" P_CHI2="1.0" P_Z="0.009905620094670844" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="2.579106644162897">
<NAME>vaginal spotting</NAME>
<DICH_DATA CI_END="173.94210213215067" CI_START="2.021146667141599" EFFECT_SIZE="18.75" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="2.240404714323651" LOG_CI_START="0.30559782980382405" LOG_EFFECT_SIZE="1.2730012720637376" ORDER="96656" O_E="0.0" SE="1.136515141415488" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" VAR="1.2916666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="173.94210213215067" CI_START="2.021146667141599" DF="0.0" EFFECT_SIZE="18.75" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="2.240404714323651" LOG_CI_START="0.30559782980382405" LOG_EFFECT_SIZE="1.2730012720637376" NO="2" P_CHI2="1.0" P_Z="0.009905620094670844" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="2.579106644162897">
<NAME>acne</NAME>
<DICH_DATA CI_END="173.94210213215067" CI_START="2.021146667141599" EFFECT_SIZE="18.75" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="2.240404714323651" LOG_CI_START="0.30559782980382405" LOG_EFFECT_SIZE="1.2730012720637376" ORDER="96657" O_E="0.0" SE="1.136515141415488" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" VAR="1.2916666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="37.81373004930149" CI_START="2.612506722906416" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="9.939246650122357" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="1.5776495194659104" LOG_CI_START="0.4170574167142882" LOG_EFFECT_SIZE="0.9973534680900993" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="7.555495301146706E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="3.368585522300515">
<NAME>Satisfaction with treatment</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="37.81373004930149" CI_START="2.612506722906416" EFFECT_SIZE="9.939246650122357" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" LOG_CI_END="1.5776495194659104" LOG_CI_START="0.4170574167142882" LOG_EFFECT_SIZE="0.9973534680900993" ORDER="96658" O_E="4.9411764705882355" SE="0.681737546179866" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" VAR="2.151620006291287" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.658908802879015" CI_START="1.3410911971209851" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="3.934577276179633E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="3.544433511604548">
<NAME>Weight gain</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.658908802879015" CI_START="1.341091197120985" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="0.4" ORDER="96659" SD_1="2.3" SD_2="2.6" SE="0.8463975950396415" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.430255407335218E-31" CI_END="-1.7343998660531081" CI_START="-5.265600133946893" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.5000000000000004" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.07" NO="7" P_CHI2="0.0" P_Q="1.0" P_Z="1.0220652218883353E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="3.885293059281411">
<NAME>AFS scores, total - 12 months (six months after stopping treatment)</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="-1.7343998660531077" CI_START="-5.265600133946892" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="4.3" ORDER="96660" SD_1="0.4" SD_2="3.1" SE="0.9008329478876759" STUDY_ID="STD-Kauppila-1988" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.2236460758551324" CI_START="-3.023646075855133" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.4061817727711984" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="12" UNITS="" WEIGHT="100.0" Z="0.8306316227273178">
<NAME>AFS scores, total - change in</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="1.2236460758551324" CI_START="-3.023646075855133" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="-5.4" MEAN_2="-4.5" ORDER="96661" SD_1="4.1" SD_2="0.8" SE="1.083512805646523" STUDY_ID="STD-Kauppila-1988" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.2956617970739879" CI_START="-3.904338202926012" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.02254094021343257" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="16" UNITS="" WEIGHT="100.0" Z="2.281126875692988">
<NAME>AFS scores, peritoneal and ovarian - 12 months (six months after stopping treatment)</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="-0.29566179707398765" CI_START="-3.9043382029260125" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="3.1" ORDER="96662" SD_1="1.5" SD_2="3.4" SE="0.9205976319760985" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.736287885148977" CI_START="0.4391322406291763" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.719918949406816" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.82842063910026" LOG_CI_START="-0.35740467627905936" LOG_EFFECT_SIZE="0.23550798141060028" METHOD="PETO" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.43626968409579914" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="0.7785078554995322">
<NAME>Resolution of endometriotic implants at laparoscopy</NAME>
<GROUP_LABEL_1>Danazol</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="6.736287885148977" CI_START="0.4391322406291763" EFFECT_SIZE="1.719918949406816" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.82842063910026" LOG_CI_START="-0.35740467627905936" LOG_EFFECT_SIZE="0.23550798141060028" ORDER="96663" O_E="1.117647058823529" SE="0.6965596601837923" STUDY_ID="STD-Telimaa-1987b" TOTAL_1="18" TOTAL_2="16" VAR="2.061025479710601" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-11 12:52:48 +1300" MODIFIED_BY="jane clarke">
<APPENDIX ID="APP-01" MODIFIED="2008-11-11 12:52:48 +1300" MODIFIED_BY="jane clarke" NO="1">
<TITLE MODIFIED="2008-11-11 12:52:46 +1300" MODIFIED_BY="jane clarke">Search string</TITLE>
<APPENDIX_BODY MODIFIED="2008-11-11 12:52:48 +1300" MODIFIED_BY="jane clarke">
<P>MEDLINE (1950 to April Week 3 2007)</P>
<P>1 endometriosis/ (11531)<BR/>2 adenomyosis.tw. (996)<BR/>3 endometrio$.tw. (12163)<BR/>4 or/1-3 (15147)<BR/>5 Danazol/ (1950)<BR/>6 danazol.tw. (1838)<BR/>7 (azol or cyclomen or danatrol or danazant or danocrine or danol or danoval).tw. (76)<BR/>8 (ladogal or norciden or panacrine).tw. (3)<BR/>9 or/5-8 (2404)<BR/>10 4 and 9 (848)<BR/>11 randomised controlled trial.pt. (233672)<BR/>12 controlled clinical trial.pt. (74707)<BR/>13 Randomized Controlled Trials/ (48151)<BR/>14 Random allocation/ (57661)<BR/>15 Double-blind method/ (90848)<BR/>16 Single-blind method/ (10848)<BR/>17 or/11-16 (396309)<BR/>18 clinical trial.pt. (434900)<BR/>19 exp clinical trials/ (190060)<BR/>20 (clin$ adj25 trial$).ti,ab,sh. (128953)<BR/>21 ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).ti,ab,sh. (90139)<BR/>22 Placebos/ (26065)<BR/>23 placebo$.ti,ab,sh. (114213)<BR/>24 random$.ti,ab,sh. (488137)<BR/>25 Research design/ (47102)<BR/>26 or/18-25 (863717)<BR/>27 animal/ not (human/ and animal/) (3077794)<BR/>28 17 or 26 (870958)<BR/>29 28 not 27 (798160)<BR/>30 10 and 29 (156)<BR/>31 (200412$ or 2005$ or 2006$ or 2007$).ed. (1527294)<BR/>32 30 and 31 (7)<BR/>33 from 32 keep 1-7 (7)</P>
<P>EBM Reviews - Cochrane Central Register of Controlled Trials (2nd quarter 2007)</P>
<P>1 endometriosis/ (338)<BR/>2 adenomyosis.tw. (19)<BR/>3 endometrio$.tw. (577)<BR/>4 or/1-3 (621)<BR/>5 Danazol/ (177)<BR/>6 danazol.tw. (271)<BR/>7 (azol or cyclomen or danatrol or danazant or danocrine or danol or danoval).tw. (7)<BR/>8 (ladogal or norciden or panacrine).tw. (0)<BR/>9 or/5-8 (284)<BR/>10 4 and 9 (142)<BR/>11 from 10 keep 1-142 (142)</P>
<P>CINAHL - Cumulative Index to Nursing &amp; Allied Health Literature (1982 to April Week 3 2007)</P>
<P>1 endometriosis/ (446)<BR/>2 adenomyosis.tw. (21)<BR/>3 endometrio$.tw. (397)<BR/>4 or/1-3 (541)<BR/>5 Danazol/ (47)<BR/>6 danazol.tw. (39)<BR/>7 (azol or cyclomen or danatrol or danazant or danocrine or danol or danoval).tw. (1)<BR/>8 (ladogal or norciden or panacrine).tw. (1)<BR/>9 or/5-8 (68)<BR/>10 4 and 9 (20)<BR/>11 exp clinical trials/ (43534)<BR/>12 Clinical trial.pt. (20632)<BR/>13 (clinic$ adj trial$1).tw. (10183)<BR/>14 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$3 or mask$3)).tw. (6101)<BR/>15 Randomi?ed control$ trial$.tw. (8914)<BR/>16 Random assignment/ (15102)<BR/>17 Random$ allocat$.tw. (1021)<BR/>18 Placebo$.tw. (8530)<BR/>19 Placebos/ (3470)<BR/>20 Quantitative studies/ (3182)<BR/>21 Allocat$ random$.tw. (60)<BR/>22 or/11-21 (61045)<BR/>23 10 and 22 (6)<BR/>24 from 23 keep 1-6 (6)</P>
<P>EMBASE (1980 to 2007 Week 16)</P>
<P>1 endometriosis/ (9383)<BR/>2 adenomyosis.tw. (886)<BR/>3 endometrio$.tw. (10448)<BR/>4 or/1-3 (12980)<BR/>5 DANAZOL/ (4834)<BR/>6 danazol.tw. (1813)<BR/>7 (azol or cyclomen or danatrol or danazant or danocrine or danol or danoval).tw. (481)<BR/>8 (Chronogyn or Danokrin or ladogal or norciden or panacrine).tw. (12)<BR/>9 or/5-8 (4989)<BR/>10 4 and 9 (1326)<BR/>11 Controlled study/ or randomised controlled trial/ (2394072)<BR/>12 double blind procedure/ (63565)<BR/>13 single blind procedure/ (6516)<BR/>14 crossover procedure/ (18516)<BR/>15 drug comparison/ (81250)<BR/>16 placebo/ (97296)<BR/>17 random$.ti,ab,hw,tn,mf. (365334)<BR/>18 latin square.ti,ab,hw,tn,mf. (1063)<BR/>19 crossover.ti,ab,hw,tn,mf. (32445)<BR/>20 cross-over.ti,ab,hw,tn,mf. (11244)<BR/>21 placebo$.ti,ab,hw,tn,mf. (145658)<BR/>22 ((doubl$ or singl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).ti,ab,hw,tn,mf. (105970)<BR/>23 (comparative adj5 trial$).ti,ab,hw,tn,mf. (5721)<BR/>24 (clinical adj5 trial$).ti,ab,hw,tn,mf. (480555)<BR/>25 or/11-24 (2873461)<BR/>26 nonhuman/ (2870879)<BR/>27 animal/ not (human/ and animal/) (12846)<BR/>28 or/26-27 (2874481)<BR/>29 25 not 28 (1687251)<BR/>30 10 and 29 (351)<BR/>31 (200412$ or 2005$ or 2006$ or 2007$).em. (1388022)<BR/>32 30 and 31 (43)<BR/>33 from 32 keep 1-43 (43)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>